Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-479 in Healthy Adult Participants
NCT07433179Phase 1Recruiting
- Sponsor
- Septerna
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of SEP-479 (3 arms), sponsored by Septerna. Primary endpoint: Frequency of treatment emergent adverse events at 2 months. Started Mar 2026; status: recruiting.
02
Drugs
SEP-479
Beyond the preview
Go deeper on NCT07433179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07433179.